氨基酸Schiff碱及其金属配合物的抑菌抗癌活性的研究进展

氨基酸Ｓｃｈｉｆｆ碱及其金属配合物具有良好的生理、生物活性,本文就近年来国内外在氨基酸Ｓｃｈｉｆ碱及其金属配合的抑菌抗癌活性的研究进展方面进行了综述     

用X-粉晶衍射法研究氨基酸配合物

研究了金属钴离子与Ｌ－赖氨酸配合物的合成方法,并用Ｘ－粉晶衍射对钴离子氨基酸配合物进行了分析鉴定。     

两面针化学成分、药理活性及抗肿瘤机制研究进展

本文主要结合近几年的国内外研究报道,综述了中国传统中草药-两面针的化学成分、药理活性及临床疗效等方面的研究进展;并结合作者所在课题组的研究成果,重点介绍了两面针生物碱及其金属配合物的抗肿瘤活性研究。     

二氢杨梅素结构修饰及生物活性研究进展

二氢杨梅素是一种二氢黄酮醇,具有抗菌、抗炎、抗肿瘤以及保肝护肝等多种生物活性。由于其结构中的6个羟基导致其脂溶性差及生物利用度低,因此对其进行结构修饰以期提高生物利用度和生物活性。本文综述了二氢杨梅素的化学法结构修饰及其生物活性等研究工作,化学修饰方法涉及醚化反应、酯化反应和金属配合物等方法,合成的衍生物具有抗病毒、抗菌、抗氧化、神经保护以及抑制肿瘤细胞增殖等活性,并且提出二氢杨梅素结构修饰过程中存在的挑战及发展方向,为更好地开发二氢杨梅素衍生物提供技术服务。     

磷光过渡金属配合物用于生物成像及癌症治疗的研究进展

顺铂及其衍生物在抗肿瘤方面取得了很大成功,但是传统的铂类抗癌药物的毒副作用和耐药性限制了这类化合物在临床上的进 一步开发。近年来,非铂类化合物,如具有 d6 电子结构的磷光过渡金属钌 ( II )、铱 ( III ) 和铼 ( I ) 配合物,由于其丰富的光物理和 光化学性质、氧化还原性质、多样的几何构型和水溶性好等优势吸引了越来越多的关注。综述上述 3 种金属配合物在生物成像及抗肿 瘤方面的研究进展。     

稀土及其配合物在生物医药上的研究进展

稀土属于化学周期表中镧系元素,具有独特生物活性,能与具有特定生理活性的配体形成稀土配合物。简要归纳了稀土配合物的种类及特点,并阐述了稀土及其配合物在细菌,真菌,癌细胞,正常细胞和病毒方面的生物效应,指出稀土及其配合物在生物医药领域方面有很大的应用前景。     

氨基酸硫酸镧固体配合物热分解过程研究

报道了用ＴＧ—ＤＴＧ法研究七个氨基酸硫酸镧固体配合物的热分解过程。研究表明,配合物有一系列分解阶段,多数均经生成低水合物、无水盐等过程。最终分解产物均为氧化镧。     

镍离子──氨基酸配合物的合成及其分析

本文着重研究了镍离子与两种氨基酸配合物的合成,并对配合物的结构进行了分析。     

稀土Ho-吲哚-3-乙酸配合物的合成及其生物活性的研究

以吲哚-3-乙酸为配体,合成了稀土钬的配合物。利用元素分析、红外光谱(IR)、热重-差热分析(TG-DTG)和荧光光谱(FS)等分析手段对配合物的组成和光学等性质进行了分析与表征,推测配合物的通式为Ho(L)3.2H2O;通过对荧光光谱的研究表明,稀土钬配合物具有较好的荧光性能;通过对其生物活性的表征说明吲哚乙酸与稀土硝酸盐在形成稀土配合物后,对植物的生长起到了协同促进作用。     

一类新型的抗菌活性肽——生物防御素（Defensin）

生物防御素（ｄｅｆｅｎｓｉｎ）是近年来发现的一组新型抗菌活性肽。它们通常都是由３５～５０个氨基酸残基组成,且分子内富含二硫键。由于其具有牢固的分子骨架、广泛的分布以及生物活性功能,因而对它们的研究已成为当前国际学术界中一个引人关注的研究热点。本文将简述有关生物防御素的分布、分子结构特征、生物活性及其可能的作用机制等方面的研究概括及展望。     

氨基酸Schiff碱金属配合物的研究进展

本文概述了近年来国内外在氨基酸Ｓｃｈｉｆ碱金属配合物领域的研究进展。简介了它们的合成方法和在金属离子分析、药物化学、生物模拟、氨基酸的合成及拆分上的应用。     

Beyond nucleic acid base pairs: from triads to heptads

Hydrogen-bonded base pairs are an important determinant of nucleic acid structure and function. However, other interactions such as base-base stacking, base-backbone, and backbone-backbone interactions as well as effects exerted by the solvent and by metal or NH(4)(+) ions also have to be taken into account. In addition, hydrogen-bonded base complexes involving more than two bases can occur. With the rapidly increasing number and structural diversity of nucleic acid structures known at atomic detail higher-order hydrogen-bonded base complexes, base polyads, have attracted much interest. This review provides an overview on the occurrence of base polyads in nucleic acid structures and describes computational studies on these nucleic acid building blocks.     

Synthesis and study of physico-chemical properties of a new chiral Schiff base ligand and its metal complex

A new chiral amino acid Schiff base ligand (Salarg) and its metal complex (Mn-Salarg) have been synthesized using l-Arginine, a naturally occurring chiral diamine with two kinds of asymmetric α-, ε-NH₂ groups. This new Salarg-ligand and Mn-Salarg complex are characterized with the help of ultraviolet, fluorescence and infrared spectroscopy. Their crystal systems are determined by X-ray powder diffraction method. The elemental analysis has been carried out by energy dispersive X-ray analysis (EDAX). The presence and percentage of metal in the complex have been detected and estimated by energy dispersive X-ray fluorescence (EDXRF) spectroscopy. Circular dichroism spectroscopy has revealed the chiral nature of the Salarg-ligand and its metal complex. Furthermore, a comparative study of this new chiral Salarg-ligand and its complex has been made with the well known achiral Salen ligand and its metal complex (Mn-Salen).     

Synthesis of messenger and ribosomal RNA precursors in isolated nuclei of the cellular slime mold Dictyostelium discoideum

When incubated with all four ribonucleoside triphosphates, isolated nuclei of the cellular slime mold, Dictyostelium discoideum, will synthesize RNA linearly for 10 to 50 minutes, depending on the salt concentration of the reaction. A fraction (10 to 30%) of the RNA labeled in isolated nuclei binds to immobilized polyuridylic acid. By the following criteria this RNA species is identical to the messenger RNA precursor characterized in whole cells: (a) both contain polyadenylic acid sequences of identical size; (b) they have the same base composition; (c) they have the same mean size as determined by dimethylsulfoxide—sucrose centrifugation; (d) they renature to excess nuclear DNA with similar kinetics; and (e) synthesis of both RNAs is resistant to 2 to 3 μg of actinomycin D/ml. Two independent RNA polymerase activities appear to synthesize poly(A)-containing RNA in isolated nuclei. One is equally active at 0.01 m-KCl and 0.25 m-KCl and is resistant to α-amanitin; the other is considerably more active at the higher salt concentration and is sensitive to α-amanitin. By the criteria of sedimentation coefficients, base composition and sensitivity of synthesis to actinomycin D, the remainder (70 to 90%) of the RNA synthesized by isolated nuclei was identical to cellular ribosomal RNA or its precursors.     

2,4-dihydroxy benzaldehyde derived Schiff bases as small molecule Hsp90 inhibitors: Rational identification of a new anticancer lead

Hsp90 is a molecular chaperone that heals diverse array of biomolecules ranging from multiple oncogenic proteins to the ones responsible for development of resistance to chemotherapeutic agents. Moreover they are over-expressed in cancer cells as a complex with co-chaperones and under-expressed in normal cells as a single free entity. Hence inhibitors of Hsp90 will be more effective and selective in destroying cancer cells with minimum chances of acquiring resistance to them. In continuation of our goal to rationally develop effective small molecule azomethines against Hsp90, we designed few more compounds belonging to the class of 2,4-dihydroxy benzaldehyde derived imines (1–13) with our validated docking protocol. The molecules exhibiting good docking score were synthesized and their structures were confirmed by IR, ¹H NMR and mass spectral analysis. Subsequently, they were evaluated for their potential to suppress Hsp90 ATPase activity by Malachite green assay. The antiproliferative effect of the molecules were examined on PC3 prostate cancer cell lines by adopting 3-(4,5-dimethythiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay methodology. Finally, schiff base 13 emerged as the lead molecule for future design and development of Hsp90 inhibitors as anticancer agents.     

Understanding the transition states of phosphodiester bond cleavage: insights from heavy atom isotope effects

The nucleotides of DNA and RNA are joined by phosphodiester linkages whose synthesis and hydrolysis are catalyzed by numerous essential enzymes. Two prominent mechanisms have been proposed for RNA and protein enzyme catalyzed cleavage of phosphodiester bonds in RNA: (a) intramolecular nucleophilic attack by the 2'-hydroxyl group adjacent to the reactive phosphate; and (b) intermolecular nucleophilic attack by hydroxide, or other oxyanion. The general features of these two mechanisms have been established by physical organic chemical analyses; however, a more detailed understanding of the transition states of these reactions is emerging from recent kinetic isotope effect (KIE) studies. The recent data show interesting differences between the chemical mechanisms and transition state structures of the inter- and intramolecular reactions, as well as provide information on the impact of metal ion, acid, and base catalysis on these mechanisms. Importantly, recent nonenzymatic model studies show that interactions with divalent metal ions, an important feature of many phosphodiesterase active sites, can influence both the mechanism and transition state structure of nonenzymatic phosphodiester cleavage. Such detailed investigations are important because they mimic catalytic strategies employed by both RNA and protein phosphodiesterases, and so set the stage for explorations of enzyme-catalyzed transition states. Application of KIE analyses for this class of enzymes is just beginning, and several important technical challenges remain to be overcome. Nonetheless, such studies hold great promise since they will provide novel insights into the role of metal ions and other active site interactions.     

CONVERSION OF TRYPSIN TO A COPPER ENZYME: TYROSINASE/CATECHOL OXIDASE BY CHEMICAL MODIFICATION

New active sites can be introduced into naturally occurring enzymes by the chemical modification of specific amino acid residues in concert with genetic techniques. Chemical strategies have had a significant impact in the field of enzyme design such as modifying the selectivity and catalytic activity which is very different from those of the corresponding native enzymes. Thus, chemical modification has been exploited for the incorporation of active site binding analogs onto protein templates and for atom replacement in order to generate new functionality such as the conversion of a hydrolase into a peroxidase. The introduction of a coordination complex into a substrate binding pocket of trypsin could probably also be extended to various enzymes of significant therapeutic and biotechnological importance.

The aim of this study is the conversion of trypsin into a copper enzyme: tyrosinase by chemical modification. Tyrosinase is a biocatalyst (EC.1.14.18.1) containing two atoms of copper per active site with monooxygenase activity. The active site of trypsin (EC 3.4.21.4), a serine protease was chemically modified by copper (Cu⁺²) introduced p-aminobenzamidine (pABA- Cu⁺²: guanidine containing schiff base metal chelate) which exhibits affinity for the carboxylate group in the active site as trypsin-like inhibitor. Trypsin and the resultant semisynthetic enzyme preparation was analysed by means of its trypsin and catechol oxidase/tyrosinase activity. After chemical modification, trypsin-pABA-Cu⁺² preparation lost 63% of its trypsin activity and gained tyrosinase/catechol oxidase activity. The kinetic properties (K_cat, K_m, K_cat/K_m), optimum pH and temperature of the trypsin-pABA-Cu⁺² complex was also investigated.     

Synthesis of aminobenzyltriethylenetetraaminohexaacetic acid: conjugation of the chelator to protein by an alkylamine linkage

The conjugation of a chelating agent to an antibody as an anchoring site for a radionuclide is the first step in the successful preparation of a radiolabeled antibody for a diagnostic and therapeutic application. The high affinity of the protein bound chelator towards radionuclide ensures a higher selectivity in the delivery of the radionuclide to the targeted tissue. 4-Aminobenzylderivativetriethlenetetraaminohexaacetic acid (TTHA), a hexadentate chelating agent has been now prepared for conjugation with proteins in view of the higher affinity of TTHA metal ions as compared to DTPA. The latent crosslinking potential of -hydroxy aldehydes has been used to conjugate the new chelating agent to proteins through an alkylamine linkage. On incubation of amino benzyl TTHA with glycoladehyde at neutral pH and room temperature, the reagent is converted to oxoethyl amino benzyl TTHA. On addition of albumin to this reaction mixture, the oxo ethylamino benzyl TTHA generates reversible schiff base adducts with the amino groups of albumin. The reduction of the Schiff base adducts of the chelator with the protein by sodium cyanoborohydride stabilizes the schiff base adducts as stable alkylamine linkages. 4-Thiocyanatobenzyl TTHA has also been prepared and conjugated to albumin through a thiocarbamoyl linkage. Both preparations of TTHA conjugated albumin complexed with ^99mTc and ¹¹¹In, with high affinity and no decomposition of the complex was noticed for at least up to 6 hrs after the preparation. The radiolabels complexed with these TTHA -albumin conjugates could not be chased out by free DTPA. A comparison of the biodistribution of ¹¹¹In, bound to the TTHA conjugated through an alkylamine and a thiocarbamoyl linkage showed that ¹¹¹In complexed with alkylamine linked TTHA was retained in blood to a level nearly 17% higher compared to that seen with thicarbamoyl linked TTHA, one hr after the injection into mice. Thus, the alkylamine linkage appears to be more stable under the in vivo conditions. The glycolaldehyde mediated alkylation procedure offers a mild, simple and rapid method for preparation of drug-protein (antibody) conjugates.